ClinicalTrials.gg
RecruitingNCT07347431LUMENUpdated Apr 21, 2026

Large Language Model for Understanding and Monitoring Elderly Neurocognition

An observational study in Dementia, sponsored by Northumbria Healthcare NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by Northumbria Healthcare NHS Foundation Trust · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
60
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 178 studies in Dementia with a site in United Kingdom — 39 open to participants now, 58 under way, 12 of them phase 3. Dementia · United Kingdom.

Planned enrollment
39th of 54
60 · median 210
Started
2026
with 5 others
Observational
54 of 178
20 open now
Primary completion
2026-12
later than 21 of 57 live
Registered
174th of 178
by date

Among the 178 studies in Dementia with a site in United Kingdom, this one is the 39th largest by planned enrollment of the 54 observational ones that give a count, is one of 6 that started in 2026, is one of 54 observational ones, reaches primary completion later than 21 of the 57 other live ones, and was the 174th registered.

Dementia

2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.

Browse Dementia studies →

Open to participants now

39 of the 178 studies in Dementia with a site in United Kingdom are open now. Recruiting first, the newest first:

33 more — sign in →

All 39 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 178 studies in Dementia with a site in United Kingdom, or all of them as a file.
02

Study summary

Dementia affects millions of people worldwide, and early diagnosis is essential for getting the right care and support. Doctors rely on collateral histories (accounts from family members or caregivers) to understand changes in a person's memory and thinking. However, these histories can be incomplete, unstructured, or difficult to obtain, making diagnosis more challenging.

This study will test LUMEN (Large Language Model for Understanding and Monitoring Elderly Neurocognition), an AI-powered conversation tool designed to help caregivers describe their loved one's symptoms more effectively. By asking structured questions and guiding the conversation, LUMEN can create clear, well-organised reports for memory clinic doctors. This could make assessments quicker, more accurate, and less stressful for families.

We will test LUMEN in real-world clinics by asking caregivers and doctors to use it and provide feedback. We want to understand how easy it is to use, whether it could improve the quality of information shared, and how it fits into existing NHS memory clinic processes. We will also run co-production workshops with community groups to ensure the tool is accessible to people from diverse cultural and language backgrounds.

This research is exciting because it explores how artificial intelligence can improve dementia care. If successful, LUMEN could enhance the diagnostic process, reduce carer burden, and help more people access dementia support sooner. In the future, this tool could be used nationwide in memory clinics, improving care for thousands of families.

Read the detailed description
  1. Background and Rationale Dementia diagnosis relies on clinical history, cognitive assessments, and collateral information from caregivers. However, obtaining structured and reliable collateral histories is challenging due to caregiver burden, recall bias, and time constraints in memory clinics. Large language models (LLMs) have the potential to improve this process by guiding structured history-taking, extracting clinically relevant details, and standardising information gathering.

    LUMEN (Large Language Model for Understanding and Monitoring Elderly Neurocognition) is an AI-powered conversational tool designed to assist caregivers in providing structured collateral histories before clinical dementia assessments. Seed-funded by the Royal College of Psychiatrists, the Alzheimer's Research UK Northern Network and the Newcastle Biomedical Research Network, LUMEN was developed to enhance diagnostic accuracy, reduce caregiver burden, and improve workflow efficiency in memory clinics.

    This study will evaluate the feasibility, usability, and acceptability of LUMEN in real-world clinical settings through a nested qualitative feasibility study. We will recruit caregivers and clinicians to interact with LUMEN and assess its effectiveness in gathering collateral histories. The study will also incorporate co-production workshops with community groups to explore issues around language, cultural inclusivity, and accessibility. Findings will inform future refinements and a larger validation study.

  2. Research Objectives

This study aims to:

  1. Evaluate LUMEN's usability -Measure caregiver and clinician experiences using validated scales (System Usability Scale [SUS] and NASA Task Load Index [NASA-TLX]).
  2. Explore acceptability and implementation barriers and facilitators-Conduct qualitative interviews and coproduction workshops to refine LUMEN's design, ensuring accessibility across diverse user groups.
  3. Compare LUMEN's outputs to clinician assessments-Investigate the alignment between LUMEN-generated reports and clinician-elicited histories using Cohen's Kappa for inter-rater reliability.

3. Background Work Undertaken LUMEN was co-developed with clinicians and stakeholders using a Modified Delphi process involving 150 clinicians, primarily old age psychiatrists. This produced 2,600 questions mapped to validated dementia tools, ensuring clinical relevance. Early technical testing evaluated open-source LLMs (e.g., Mistral 7B, LLaMA2 7B) using simulated clinical vignettes. ROC curve analysis demonstrated an AUC of 0.89 for distinguishing dementia-related narratives, and Cohen's Kappa 0.82 indicated high inter-rater reliability between LUMEN's outputs and clinician ratings. Early PPIE (Patient and Public Involvement and Engagement) feedback highlighted the need for simpler language, cultural sensitivity, and improved user experience. These insights will be further refined through the proposed co-production workshops.

4. Study Design and Methodology This study will employ a mixed-methods approach, combining quantitative usability testing with qualitative interviews to evaluate LUMEN's feasibility and acceptability.

4.1. Participants and Recruitment

  • Carers (n=20-30 dyads): Recruited via Northumbria NHS Memory Clinics. Eligible carers will be adults (≥18 years) who know the patient well, have basic English literacy, and can provide informed consent.
  • Patients (n=20-30): Individuals (≥65 years) attending a memory clinic for cognitive assessment.
  • Clinicians (n=8-10): Specialists in dementia care (neurologists, psychiatrists, geriatricians, advanced nurse practitioners) with ≥2 years of experience.

4.2. Study Procedures

  1. Baseline Data Collection:

    • Demographics (age, gender, ethnicity, socioeconomic status).
    • Clinical diagnosis (where available).
    • Cognitive test scores (MoCA/ACE).
  2. LUMEN Interaction:

    • Carers will use LUMEN on a laptop or tablet to provide structured collateral histories (\~20-30 min).
    • Clinicians will review LUMEN-generated histories to assess completeness and clinical utility.
  3. Usability and Cognitive Load Assessment:

    • SUS (System Usability Scale): 10-item Likert-scale questionnaire assessing ease of use (score ≥70 = good usability).
    • NASA-TLX (Task Load Index): Evaluates perceived cognitive workload (scores 0-29 = low workload).
  4. Qualitative Evaluation:

    • Semi-structured interviews (n=10 carers, n=4-5 clinicians).
    • Co-production workshops with community groups to explore language, cultural representation, and accessibility.
  5. Exploratory Analysis:

    • Inter-rater reliability (Cohen's Kappa): Agreement between LUMEN outputs and clinician assessments.
    • Diagnostic accuracy (AUROC curve analysis): Comparison of LUMEN's assessments with clinical diagnoses.

5. Milestones and Timescales

The study will run for 12 months (April 2025 - April 2026), with key phases as follows:

Phase Month Activities Preparation \& Ethics 1-3 Final IRAS approval, NHS R\&D approvals, team setup Recruitment \& Data Collection 4-9 Patient-carer dyad recruitment, clinician recruitment, LUMEN testing Usability Workshops 6-8 Co-production workshops, qualitative interviews Data Analysis \& Refinement 9-10 Thematic analysis, SUS/NASA-TLX scoring, LLM refinements Final Reporting \& Next Steps 11-12 Dissemination, grant preparation for large-scale validation study 6. Expected Impact This study will generate critical feasibility data to inform a larger clinical validation study and subsequent NHS integration. Expected outcomes include:

  • A refined, co-designed LUMEN prototype with improved usability and accessibility.
  • Quantitative evidence on usability and cognitive workload, supporting future funding applications.
  • Preliminary insights into AI-assisted collateral history-taking, laying the foundation for regulatory approval as a Software as a Medical Device (SaMD).
  • Potential for early NHS adoption under the MHRA framework, streamlining dementia diagnostics.
03

Conditions studied

  • Dementia

Keywords

  • Dementia
  • Alzheimer's Disease
  • Artificial Intelligence
  • Large Language Models
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patient and carer dyads: patients attending the Memory Clinic for assessment of cognitive problems.

Clinicians: specialist doctors or advanced nurse practitioners responsible for dementia diagnosis

Eligibility criteria

Carers of patients attending Memory Clinic appointments; Aged 18 or over; Both patients and cares can provide ; Basic English literacy

Clinicians must have at least 2 years of specialist dementia care experience and be personally responsible for dementia diagnosis; Must be provide informed consent

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patient-carer dyads

    Carers (n=20-30 dyads): Recruited via Northumbria NHS Memory Clinics. Eligible carers will be adults (≥18 years) who know the patient well, have basic English literacy, and can provide informed consent. • Patients (n=20-30): Individuals (≥65 years) attending a memory clinic for cognitive assessment. 1. Baseline Data Collection: * Demographics (age, gender, ethnicity, socioeconomic status). * Clinical diagnosis (where available). * Cognitive test scores (MoCA/ACE). 2. LUMEN Interaction: o Carers will use LUMEN on a laptop or tablet to provide structured collateral histories (\~20-30 min). 3. Usability and Cognitive Load Assessment: * SUS (System Usability Scale): 10-item Likert-scale questionnaire assessing ease of use (score ≥70 = good usability). * NASA-TLX (Task Load Index): Evaluates perceived cognitive workload (scores 0-29 = low workload). 4. Qualitative Evaluation: * Semi-structured interviews (n=10 carers).

    Other: LUMEN prototype software interaction

  • Clinicians

    4.1. Participants and Recruitment • Clinicians (n=8-10): Specialists in dementia care (neurologists, psychiatrists, geriatricians, advanced nurse practitioners) with ≥2 years of experience. 4.2. Study Procedures 1. Baseline Data Collection: o Demographics (age, gender, ethnicity, socioeconomic status). 2. LUMEN Interaction: o Clinicians will review LUMEN-generated histories to assess completeness and clinical utility. 3. Usability and Cognitive Load Assessment: * SUS (System Usability Scale): 10-item Likert-scale questionnaire assessing ease of use (score ≥70 = good usability). * NASA-TLX (Task Load Index): Evaluates perceived cognitive workload (scores 0-29 = low workload). 4. Qualitative Evaluation: * Semi-structured interviews (n=4-5 clinicians).

    Other: LUMEN prototype software interaction

Interventions

  • OtherLUMEN prototype software interaction

    This is a prototype software which seeks to gather collateral information relevant to a dementia clinical assessment.

06

What researchers measure

Primary outcomes

  1. SUS (System Usability Scale)

    10-item Likert-scale questionnaire assessing ease of use (score ≥70 = good usability).

    Time frame: Immediately after use of software

  2. NASA-TLX (Task Load Index):

    Evaluates perceived cognitive workload (scores 0-29 = low workload).

    Time frame: Immediately after prototype interaction

Other outcomes

  1. Thematic analysis

    Qualitative analysis of dialogues from semi-structured interviews

    Time frame: 1-10 days after use of prototype software

07

Study locations

1 of 1 sites recruiting
08

References and documents

Related links

Individual participant data

Plan to share: Undecided — This will include personal narratives of participants' dementia journeys which may contain sensitive information

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.

Of 272 non-industry observational studies under Dementia, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 202. This study's planned 9 months is below that.

Counting every sponsor, half of 294 studies reached it within 65 months; a quarter within 29 and three quarters within 188.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2026
First posted
Jan 16, 2026
StartActual
Mar 19, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07347431
Lead sponsor
Northumbria Healthcare NHS Foundation Trust
Collaborators
Newcastle University
Responsible party
Sponsor
First posted
Jan 16, 2026
Start date
Mar 19, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 21, 2026

Study contacts

Judith R Harrison, MBChB
Contact
Judith.Harrison@newcastle.ac.uk
+441912081314
Lisa Gallagher
Contact
Lisa.gallagher@northumbria-healthcaretrust.nhs.uk
+44191 293 4087
Judith R Harrison, MBChB PhD
principal investigator · Northumbria Healthcare NHS Foundation Trust

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion